​

MiNK Therapeutics (INKT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

INKT Stock Rating

MiNK Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

INKT Price Target Upside V Benchmarks

TypeNameUpside
StockMiNK Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.55$7.55$7.55
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2512---3
May, 2513---4
Apr, 2513---4
Mar, 2513---4
Feb, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-300 $-230 $-160 $-90 $-20 $50 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.65$-285.82----
Avg Forecast$-6.51$-3.65$-2.71$-2.86$-2.70$2.40
High Forecast$-6.31$-3.58$-2.32$-2.61$-2.50$2.40
Low Forecast$-6.71$-3.71$-3.10$-3.11$-2.90$2.40
Surprise %-90.02%7730.68%----

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$4.40M$70.40M
High Forecast----$4.40M$70.40M
Low Forecast----$4.40M$70.40M
Surprise %------

Net Income Forecast

$-15B $-11B $-7B $-3B $1B $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.46M$-10.78B----
Avg Forecast$-223.67M$-125.29M$-93.17M$-98.18M$-92.77M$82.46M
High Forecast$-216.79M$-123.02M$-79.86M$-89.57M$-85.90M$82.46M
Low Forecast$-230.55M$-127.57M$-106.48M$-106.80M$-99.64M$82.46M
Surprise %-89.96%8507.63%----

INKT Forecast FAQ

Is MiNK Therapeutics stock a buy?

MiNK Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MiNK Therapeutics is a favorable investment for most analysts.

What is MiNK Therapeutics's price target?

MiNK Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $7.55.

How does MiNK Therapeutics stock forecast compare to its benchmarks?

MiNK Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for MiNK Therapeutics over the past three months?

  • June 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MiNK Therapeutics’s EPS forecast?

MiNK Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.71, marking a -99.05% decrease from the reported $-286 in 2024. Estimates for the following years are $-2.86 in 2026, $-2.7 in 2027, and $2.4 in 2028.

What is MiNK Therapeutics’s revenue forecast?

MiNK Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $4.4M for 2027, and $70.4M for 2028.

What is MiNK Therapeutics’s net income forecast?

MiNK Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-93.173M, representing a -99.14% decrease from the reported $-10.785B in 2024. Projections indicate $-98.184M in 2026, $-92.772M in 2027, and $82.46M in 2028.